Clinical Trial Update: Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluating the combination of selinexor, venetoclax, and azacitidine in newly diagnosed acute myeloid leukemia patients who are not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Selinexor (Xpovio) (Selinexor)
• Venetoclax (Venclexta) (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia, Adult | Phase 1, Phase 2 | Status: TERMINATED